Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | MAOB | P27338 | 3/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.50 |
| ▸ | MAOA | P21397 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | CNR1 | P21554 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.46 |
| ▸ | PTGES | O14684 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6836524 | 0.86 | MAPT (0.58) | MAPTMAOBCYP19A1MAOAALDH1A1 | |
| SCHEMBL6841844 | 0.85 | MAPT (0.55) | MAPTMAOBCYP19A1MAOAALDH1A1 | |
| SCHEMBL9370131 | 0.83 | CASP3 (0.51) | MAPTMEN1KMT2APOLBCTDSP1 | |
| SCHEMBL6942590 | 0.81 | MAPT (0.46) | MAPTMAOBCYP19A1MAOAALDH1A1 | |
| SCHEMBL708969 | 0.80 | MAOB (0.49) | MAOBALDH1A1MEN1KMT2APOLB | |
| SCHEMBL7791330 | 0.79 | RAB9A (0.62) | MAPTMAOBALDH1A1MEN1KMT2A | |
| SCHEMBL9599386 | 0.78 | CNR2 (0.51) | MAPTMAOBCYP19A1MAOACNR2 | |
| SCHEMBL16245017 | 0.78 | KMT2A (0.54) | MAPTALDH1A1MEN1KMT2APOLB | |
| SCHEMBL417705 | 0.77 | MAPT (0.60) | MAPTMAOBMAOAALDH1A1MEN1 | |
| SCHEMBL16396138 | 0.77 | HTT (0.59) | MAPTMAOBMAOAALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040157919-A1 | Trisubstituted carbocyclic cyclophilin binding compounds and their use | WU YONG-QIAN (US) | 2004-08-12 | — | — | US | disclosed |
| US-6656971-B2 | Non-peptidic small organic compounds having an affinity for cyclophilin (CyP)-type immunophilins; inhibiting their peptidyl-prolyl isomerase activity; treating variety of medical conditions | GUILFORD PHARMACEUTICALS INC. | 2003-12-02 | — | — | US | disclosed |
| EP-1360173-A2 | TRISUBSTITUTED CARBOCYCLIC CYCLOPHILIN BINDING COMPOUNDS AND THEIR USE | GUILFORD PHARMACEUTICALS INC. (US) | 2003-11-12 | — | — | EP | disclosed |
| US-20020165275-A1 | Trisubstituted carbocyclic cyclophilin binding compounds and their use | GUILFORD PHARMACEUTICALS INC. | 2002-11-07 | — | — | US | disclosed |
| WO-2002059080-A2 | TRISUBSTITUTED CARBOCYCLIC CYCLOPHILIN BINDING COMPOUNDS AND THEIR USE | GUILFORD PHARMACEUTICALS INC. (US) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157919-A1 | Trisubstituted carbocyclic cyclophilin binding compounds and their use | FKBP2, PPIG, FKBP8 | MAPT 1908/4885MAOB 1073/4885CYP19A1 418/4885 |
| US-20020165275-A1 | Trisubstituted carbocyclic cyclophilin binding compounds and their use | FKBP2, PPIG, FKBP8 | MAPT 1908/4885MAOB 1073/4885CYP19A1 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.